Leviaben (Levofloxacin)

Levofloxacin exerts its antibacterial effect by binding to bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA supercoiling and replication. Inhibition of these enzymes prevents DNA synthesis and transcription, leading to bacterial cell death. This mechanism is bactericidal against a broad spectrum of Gram‑negative and Gram‑positive organisms.

The dose of Leviaben is determined by the prescribing clinician based on the type and severity of the infection, patient weight, renal function, and local guidelines. Healthcare professionals select the appropriate intravenous infusion rate and duration, and the regimen is recorded in the patient’s medical order. Patients should follow the prescriber’s instructions.

Safety of levofloxacin in pregnancy and lactation has not been fully established. It is generally reserved for situations where the potential benefit outweighs potential risks to the fetus or infant. Clinicians should evaluate the indication carefully and consider alternative agents when possible.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Leviaben. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain logistics if needed—and the necessary import documentation.

Leviaben contains levofloxacin, the L‑isomer of ofloxacin, offering a broader spectrum of activity and higher potency than many older fluoroquinolones. Compared with agents such as ciprofloxacin, levofloxacin provides better coverage of Gram‑positive organisms and achieves higher lung tissue concentrations, making it a preferred option for respiratory infections requiring IV therapy.

Leviaben should be stored at 2‑8 °C (refrigerated) in its original packaging, protected from light. It must not be frozen or shaken, and any solution prepared for infusion should be used promptly according to the manufacturer’s instructions. Maintaining the cold chain preserves drug stability and potency.

Leviaben is administered by intravenous infusion, typically diluted in compatible IV fluids and infused over a period specified by the prescribing clinician, often 30‑60 minutes. Administration should be performed by qualified healthcare personnel in a clinical setting, with monitoring for infusion‑related reactions and adherence to aseptic technique.

Serious adverse reactions to levofloxacin include tendon rupture, especially in older adults or those on corticosteroids; QT‑interval prolongation leading to arrhythmias; severe hypersensitivity reactions such as anaphylaxis; Clostridioides difficile‑associated diarrhea; peripheral neuropathy; and central nervous system effects like seizures. Prompt medical evaluation is required if any of these occur.

Leviaben is contraindicated in patients with a known hypersensitivity to levofloxacin, other fluoroquinolones, or any component of the formulation. Caution is advised for individuals with a history of tendon disorders, prolonged QT interval, uncontrolled epilepsy, or severe renal impairment without dose adjustment. Pregnant or breastfeeding women should only use it when clearly justified by the prescriber.